2024
From transthyretin cardiac amyloidosis diagnosis to tafamidis treatment: Association of drop-off with patient sociodemographic characteristics
Walenczyk K, Singh A, Tong K, Burg M, Miller E. From transthyretin cardiac amyloidosis diagnosis to tafamidis treatment: Association of drop-off with patient sociodemographic characteristics. American Journal Of Health-System Pharmacy 2024, zxae183. PMID: 38963826, DOI: 10.1093/ajhp/zxae183.Peer-Reviewed Original ResearchPatient sociodemographic characteristicsATTR-CASociodemographic characteristicsSpecialty pharmacyPyrophosphate scintigraphyPopulation prevalence ratesEconomically disadvantaged areasTransthyretin cardiac amyloidosisBlack/African American raceReduce disparitiesPotential patient subgroupsPharmacy processesProportion of daysClinical pathwayCompare sociodemographicsDisadvantaged areasEquitable provisionTafamidis therapyCardiac amyloidosisTafamidis treatmentPrevalence ratesClinical programsAmerican racePatient subgroupsPosting manuscripts
2020
Psychological stress in heart failure: a potentially actionable disease modifier
Harris KM, Jacoby DL, Lampert R, Soucier RJ, Burg MM. Psychological stress in heart failure: a potentially actionable disease modifier. Heart Failure Reviews 2020, 26: 561-575. PMID: 33215323, PMCID: PMC8026548, DOI: 10.1007/s10741-020-10056-8.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsHeart failurePsychological stressHeart failure symptomsHeart failure patientsLife stressorsDisease-related consequencesQuality of lifePatterns of exposureAdverse eventsFailure patientsDisease courseEjection fractionPatients' qualityModifiable factorsPatient subgroupsSymptom exacerbationDaily life stressorsFailure symptomsPathophysiological pathwaysEffective diseaseFunctional limitationsDiminished qualityPatientsActionable pathwaysStress exposure